Therefore, these results indicate that WT1126-specific CTLs proliferated in the immune response against the WT1 antigen of tumor cells in PTs, may differentiate from naïve to terminal effector phenotypes, and may clonally expand during this cell differentiation in association with the continuous proliferation of WT1126-specific CTLs, leading to higher clonality of WT1126-specific CTLs. The gene discussed is WT1; the disease is neoplasm.